NCT04276688View on ClinicalTrials.gov

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

March 30, 2020

Study Completion Date

March 31, 2020

Conditions
Novel Coronavirus Infection
Interventions
DRUG

Lopinavir/ritonavir

400mg/100mg twice daily for 14 days

DRUG

Ribavirin

400mg twice daily for 14 days

DRUG

Interferon Beta-1B

0.25mg subcutaneous injection alternate day for 3 days

Trial Locations (1)

Unknown

University of Hong Kong, Queen Mary Hospital, Hong Kong

All Listed Sponsors
collaborator

Hospital Authority, Hong Kong

OTHER_GOV

lead

The University of Hong Kong

OTHER

NCT04276688 - Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | Biotech Hunter | Biotech Hunter